Bravecto Quantum is a drug owned by INTERVET, INC. It is protected by 2 US drug patents filed from 2027 to 2040. All patents are active. Details of Bravecto Quantum’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US7662972 | 28 Jun, 2027 | Active |
Exclusivity Information
Bravecto Quantum holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Bravecto Quantum's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Jul 10, 2028 |
About Bravecto Quantum
Bravecto Quantum is a drug
owned by INTERVET, INC.
Bravecto Quantum uses
Fluralaner as the active
ingredient.
Active Ingredient:
Bravecto Quantum uses
Fluralaner as the active ingredient.
Check out other Drugs and Companies using
Fluralaner ingredient.